| Target Professions: | DO, MD, Nurse Practitioner, Nurse, Physician Associate/Assistant |
| Target Specialties: | Hematology, Hematology/Oncology, Oncology |
| Credits Available: | 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC |
Despite significant advancements in treatment, multiple myeloma remains an incurable disease, and nearly all patients experience relapse, often requiring increasingly complex therapeutic strategies.
With the rapid expansion of treatment options, particularly novel targeted therapies such as GPRC5D-directed approaches, the landscape of relapsed/refractory multiple myeloma (RRMM) management is evolving at an unprecedented pace. While these agents offer deep and durable remissions, their integration into clinical practice presents challenges in sequencing, toxicity management, and multidisciplinary coordination.
This educational initiative is designed to empower clinicians with the latest insights on GPRC5D-targeted therapies, facilitate the exchange of real-world clinical experience, and provide actionable strategies for optimizing patient outcomes. Through interactive discussions and expert-led guidance, participants will gain practical knowledge to navigate the complexities of RRMM treatment while fostering collaborative networks to enhance long-term patient care.
Join us to stay at the forefront of innovation in multiple myeloma management and elevate your clinical practice.
Get a sense of where you stand with GPRC5D-targeted therapies in RRMM and discover areas to enhance your knowledge.
Explore GPRC5D-targeted therapy in RRMM, comparing mechanisms with BCMA-targeted agents, patient selection, treatment sequencing, combination strategies, and proactive management of unique adverse events in clinical practice.
Learn to identify and manage adverse events linked to GPRC5D-targeted therapies, including CRS, ICANS, and skin/nail toxicities, through clinical data, expert insights, and best practices for mitigating treatment-related risks.
Learn to assess patient eligibility for GPRC5D-targeted therapy and evaluate sequencing strategies in RRMM, balancing disease burden, prior BCMA therapy, and treatment tolerability for optimal outcomes.
Take a moment to review key insights on GPRC5D-targeted therapies in RRMM and solidify your learning for real-world application.
Attend an interactive discussion on the evolving role of GPRC5D-targeted therapies in relapsed/refractory multiple myeloma. Explore real-world challenges, patient selection strategies, and emerging clinical data in a collaborative learning environment.
Explore management of a 68-year-old woman with RRMM progressing after VRd and DPd, presenting with anemia, bone pain, renal insufficiency, hypertension, rising paraproteins, desiring aggressive treatment options.
Manage MJ, a 75-year-old man with triple-class refractory RRMM experiencing dysgeusia, decreased appetite, weight loss, skin dryness, and nail irritation two weeks into GPRC5D-targeted therapy (talquetamab).
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with RRMM.
Engage in a dynamic conversation on integrating GPRC5D-targeted therapies into patient care. Share experiences, discuss case-based scenarios, and gain practical strategies to optimize treatment decisions for RRMM.
